公开(公告)号：US11460474B2

公开(公告)日：2022-10-04

申请号：US16257770

申请日：2019-01-25

Applicant: Roche Diagnostics Operations, Inc.

Inventor： Dirk Block ,  Hanspeter Brunner ,  Thomas Dieterle ,  Ursula-Henrike Wienhues-Thelen ,  Christian Zaugg ,  Andre Ziegler

IPC: G01N33/543 ,  G01N33/68 ,  A61K31/40 ,  G01N33/62

Abstract: The present disclosure is directed to a method of identifying a patient having heart failure as likely to respond to a therapy with a statin. The method is based on measuring the level of at least one marker selected from GDF-15 (Growth Differentiation Factor 15), Urea, SHBG (Sex Hormone-Binding Globulin), Uric acid, PLGF (Placental Growth Factor), IL-6 (Interleukin-6), Transferrin, a cardiac Troponin, sFlt-1 (Soluble fms-like tyrosine kinase-1), Prealbumin, Ferritin, Osteopontin, sST2 (soluble ST2), and hsCRP (high sensitivity C-reactive protein) in a sample from a patient. Further envisaged is a method of predicting the risk of a patient to suffer from death or hospitalization, wherein the patient has heart failure and undergoes a therapy with a statin. The method is also based on the measurement of the level of at least one of the aforementioned markers.

公开(公告)号：US10345315B2

公开(公告)日：2019-07-09

申请号：US15274533

申请日：2016-09-23

Applicant: Roche Diagnostics Operations, Inc.

Inventor： Johann Karl ,  Ursula-Henrike Wienhues-Thelen ,  Dirk Block ,  Christian Zaugg ,  Hans-Peter Brunner ,  James Januzzi ,  Andre Ziegler ,  Julian Braz ,  Thomas Dieterle ,  Edelgard Kaiser

IPC: G01N33/50 ,  G01N33/68

Abstract: Disclosed herein is a method for diagnosing and/or grading diastolic dysfunction or at least one structural or functional abnormality associated with diastolic dysfunction. The method involves measuring the level of IGFBP7 (Insulin like growth factor binding protein 7) and, optionally, the level of at least one further marker in a patient suffering from heart failure, and comparing the level to a reference level. Also disclosed is a method of monitoring diastolic function in a patient suffering from heart failure, and kits and devices for performing the method.

公开(公告)号：US20150233946A1

公开(公告)日：2015-08-20

申请号：US14705528

申请日：2015-05-06

Applicant: Roche Diagnostics Operations, Inc.

Inventor： Dirk Block ,  Roberto Latini ,  Serge Masson ,  Ursula-Henrike Wienhues-Thelen ,  Christian Zaugg ,  Andre Ziegler

IPC: G01N33/68

CPC classification number: G01N33/6887 ,  G01N33/6869 ,  G01N33/6893 ,  G01N2333/4712 ,  G01N2333/4737 ,  G01N2333/4745 ,  G01N2333/5412 ,  G01N2333/58 ,  G01N2800/326 ,  G01N2800/52

Abstract: The present invention relates to a method for diagnosing a recent paroxysmal atrial fibrillation. The method is based on the determination of the at least one marker selected from the group consisting of a cardiac Troponin, NT-proBNP (N-terminal prohormone of brain natriuretic peptide), hsCRP, IL-6 (Interleukin-6) and IGFBP7 (Insulin like growth factor binding protein 7) in a sample from the subject, and on the comparison of the, thus, determined amount(s) with a reference amount (reference amounts). Further, the present invention relates to a method for identifying a subject being treatable with anticoagulation therapy. Further envisaged are systems, reagents and kits used in performing the methods disclosed herein.

Abstract translation: 本发明涉及一种诊断近期阵发性房颤的方法。 该方法基于选自心肌肌钙蛋白，NT-proBNP（脑钠尿肽的N-末端激素原），hsCRP，IL-6（白细胞介素-6）和IGFBP7（ 来自受试者的样品中的胰岛素样生长因子结合蛋白7），以及由此确定的量与参考量（参考量）的比较。 此外，本发明涉及用抗凝治疗来鉴别受治疗者的方法。 进一步设想的是用于执行本文公开的方法的系统，试剂和试剂盒。

公开(公告)号：US20230341419A1

公开(公告)日：2023-10-26

申请号：US18021047

申请日：2021-08-12

Applicant: Roche Diagnostics Operations, Inc.

Inventor： Vinzent Rolny ,  Ursula-Henrike Wienhues-Thelen ,  Andre Ziegler ,  David Conen ,  Stefan Osswald ,  Michael Kuehne ,  Peter Kastner

IPC: G01N33/68

CPC classification number: G01N33/6896 ,  G01N2800/2871 ,  G01N2800/52 ,  G01N2800/50

Abstract: The present invention relates to a method for assessing whether a subject has experienced one or more silent infarcts in a subject, said method comprising a) determining the amount of the biomarker ESM-1 in a sample from the subject, b) comparing the amount determined in step a) to a reference, and c) assessing whether a subject has experienced one or more silent infarcts. The present invention further relates to a method for predicting silent infarcts and/or cognitive decline, and methods for assessing and monitoring of the extent of silent small and large noncortical and cortical infarcts in a subject. Further encompassed by the present invention are the corresponding uses.

公开(公告)号：US20210156875A1

公开(公告)日：2021-05-27

申请号：US17161998

申请日：2021-01-29

Applicant: Roche Diagnostics Operations, Inc. ,  Universitaet Maastricht ,  Academisch Ziekenhuis Maastricht

Inventor： Johann Karl ,  Peter Kastner ,  Roberto Latini ,  Vinzent Rolny ,  Ursula-Henrike Wienhues-Thelen ,  Andre Ziegler ,  Manuel Dietrich ,  Jennifer Meessen ,  Ulrich Schotten

IPC: G01N33/68

Abstract: The present invention relates to a method for assessing atrial fibrillation in a subject, said method comprising the steps of determining the amount of DKK3 in a sample from the subject, and comparing the amount of DKK3 to a reference amount, whereby atrial fibrillation is to be assessed. Moreover, the present invention relates to a method for diagnosing heart failure and/or at least one structural or functional abnormality of the heart associated with heart failure.

公开(公告)号：US20190277861A1

公开(公告)日：2019-09-12

申请号：US16420385

申请日：2019-05-23

Applicant: Roche Diagnostics Operations, Inc.

Inventor： Johann Karl ,  Ursula-Henrike Wienhues-Thelen ,  Dirk Block ,  Christian Zaugg ,  Hans-Peter Brunner ,  James Januzzi ,  Andre Ziegler ,  Julian Braz ,  Thomas Dieterle ,  Edelgard Kaiser

IPC: G01N33/68

Abstract: The present disclosure relates to a method for diagnosing and/or grading diastolic dysfunction or at least one structural or functional abnormality associated with diastolic dysfunction. The method involves measuring the level of IGFBP7 (Insulin like growth factor binding protein 7) and, optionally, the level of at least one further marker in a patient suffering from heart failure, and comparing the level to a reference level. Further envisaged is a method of monitoring diastolic function in a patient suffering from heart failure. Also encompassed by the present disclosure are kits and devices adapted to carry out the method of the present invention.

公开(公告)号：US11946938B2

公开(公告)日：2024-04-02

申请号：US16899629

申请日：2020-06-12

Applicant: Roche Diagnostics Operations, Inc.

Inventor： Ursula-Henrike Wienhues-Thelen ,  Johann Karl ,  Peter Kastner ,  Vinzent Rolny ,  Andre Ziegler ,  David Conen

IPC: G01N33/53 ,  G01N33/68

CPC classification number: G01N33/6893 ,  G01N2333/4745 ,  G01N2333/515 ,  G01N2800/326 ,  G01N2800/50

Abstract: The present disclosure demonstrates a method for predicting the risk of stroke of a subject and a method for improving the prediction accuracy of a clinical stroke risk score. The methods are based on the determination of the amount of Angiopoietin-2 (Ang-2) and/or the amount of Insulin-like growth factor-binding protein 7 (IGFBP7) in a sample from a subject. Moreover, disclose is the use of i) the biomarker Ang-2 and/or the biomarker IGFBP7, and/or ii) at least one detection agent that specifically binds to Ang-2 and/or at least one detection agent that specifically binds to IGFBP7 in a sample from a subject for predicting the risk of stroke of said subject.

公开(公告)号：US20230314452A1

公开(公告)日：2023-10-05

申请号：US18021085

申请日：2021-08-12

Applicant: Roche Diagnostics Operations, Inc.

Inventor： Peter Kastner ,  Vinzent Rolny ,  Ursula-Henrike Wienhues-Thelen ,  Andre Ziegler ,  David Conen ,  Stefan Osswald ,  Michael Kuehne

IPC: G01N33/68

CPC classification number: G01N33/6896 ,  G16H50/30

Abstract: The present invention relates to a method for assessing whether a subject has experienced one or more silent infarcts in a subject, said method comprising a) determining the amount of IGFBP7 in a sample from the subject, b) comparing the amount determined in step a) to a reference, and c) assessing whether a subject has experienced one or more silent infarcts. The present invention further relates to a method for predicting silent infarcts and/or cognitive decline, and methods for assessing and monitoring of the extent of silent small and large noncortical and cortical infarcts in a subject. Further encompassed by the present invention are the corresponding uses.

公开(公告)号：US20210181211A1

公开(公告)日：2021-06-17

申请号：US17176797

申请日：2021-02-16

Applicant: Roche Diagnostics Operations, Inc. ,  Universiteit Maastricht ,  Academisch Zickenhuis Maastricht

Inventor： Peter Kastner ,  Andre Ziegler ,  Ursula-Henrike Wienhues-Thelen ,  Vinzent Rolny ,  Manuel Dietrich ,  Ulrich Schotten

IPC: G01N33/68

Abstract: The present invention relates to a method for assessing atrial fibrillation in a subject, said method comprising the steps of determining the amount of TFPI-2 in a sample from the subject, and comparing the amount of TFPI-2 to a reference amount, whereby atrial fibrillation is to be assessed. Moreover, the present invention relates to methods for assessing anticoagulation therapy and to methods for predicting the risk of stroke of a subject. Said methods are based on the determination of the amount of TFPI-2 in a sample from the subject.

公开(公告)号：US20200300869A1

公开(公告)日：2020-09-24

申请号：US16899629

申请日：2020-06-12

Applicant: Roche Diagnostics Operations, Inc.

Inventor： Ursula-Henrike Wienhues-Thelen ,  Johann Karl ,  Peter Kastner ,  Vinzent Rolny ,  Andre Ziegler ,  David Conen

IPC: G01N33/68

Abstract: The present disclosure demonstrates a method for predicting the risk of stroke of a subject and a method for improving the prediction accuracy of a clinical stroke risk score. The methods are based on the determination of the amount of Angiopoietin-2 (Ang-2) and/or the amount of Insulin-like growth factor-binding protein 7 (IGFBP7) in a sample from a subject. Moreover, disclose is the use of i) the biomarker Ang-2 and/or the biomarker IGFBP7, and/or ii) at least one detection agent that specifically binds to Ang-2 and/or at least one detection agent that specifically binds to IGFBP7 in a sample from a subject for predicting the risk of stroke of said subject.